secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0000950170-22-014223
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q2 2022 revenue $18.5M; cash $580.8M; FT516 RMAT meeting set
------------------------------------------------------------------------------

- Q2 2022 collaboration revenue $18.5M from Janssen and ONO; R&D expense $81.3M, G&A $20.4M; cash $580.8M at June 30.
- FT516 RMAT meeting with FDA scheduled for 3Q22 to discuss registrational pathways for relapsed/refractory aggressive B-cell lymphoma.
- First patient dosed with FT536 CAR MICA/B NK cell product candidate for advanced solid tumors; multi-dose enrollment ongoing.
- Janssen exercised commercial option for first iPSC-derived CAR NK collaboration program; first IND planned 2H22.
- Expanded ONO collaboration: second solid tumor antigen program added, both CAR NK and CAR T candidates in development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022014223/0000950170-22-014223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022014223/fate-20220803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer